DOI QR코드

DOI QR Code

Resveratrol Upregulates p21, Cell Cycle Regulator, in Gaucher Disease Cells

Gaucher병에서 resveratrol의 세포주기 조절자 p21을 통한 세포보호 효과 연구

  • Kim, Dong-Hyun (Department of biotechnology, Hoseo University) ;
  • Heo, Tae-Hwe (College of Pharmacy, The Catholic University of Korea) ;
  • Kim, June-Bum (Department of Pediatrics, Konyang University College of Medicine) ;
  • Kim, Sung-Jo (Department of biotechnology, Hoseo University)
  • 김동현 (호서대학교 생명공학과) ;
  • 허태회 (가톨릭대학교 약학대학) ;
  • 김준범 (건양대학교 의과대학 소아청소년과) ;
  • 김성조 (호서대학교 생명공학과)
  • Received : 2010.07.30
  • Accepted : 2010.08.18
  • Published : 2010.08.30

Abstract

Gaucher disease (GD) is caused by glucocerebrosidase functional deficiency and the most prevalent lysosomal storage disorder (LSD), with an incidence of about 1 in 20,000 new births. Resveratrol, one kind of phytoalexin, is a produced naturally by several plants and has anti-tumor, anti-aging, anti-inflammatory and neuro-protective effects. In this paper we provide the cellular protective effect of resveratrol in both type I and type II Gaucher disease cells. Resveratrol treatment did not show any significant change in the p21 and p53 mRNA expression level, however expression level of the p21 protein, a cell cycle arrest factor, shows significant increment in both types of Gaucher disease cells. These cell cycle arrest patterns were confirmed by both MTT assay measurement and microscopy detection. In comparison, expression level of poly ADP ribose polymerase (PARP), an apoptosis indicator protein, was significantly decreased in both type I and II Gaucher disease cells after treatment with resveratrol. This result indicates that resveratrol relievescellular apoptotic stress fromtype I and II Gaucher disease cells. Therefore, we demonstrate that resveratrol inhibits cell proliferation via p21 activity and activates cellular repair systems for Gaucher disease cells. Our results provide at least one of the molecular mechanisms of Gaucher disease and may allow the verification of potential drug targets for therapeutic trials.

고셔병은 세포내의 글루코세레브로시데이즈의 결핍으로 인하여 리소좀 내의 글루코세레브로사이드가 분해되지 못하고 축적되는 질환으로 알려져 있으며, 유형의 종류에 따라 신경퇴행성 질환으로 나타나는 것으로 보고되어 있으나 아직까지 정확한 기전이 밝혀져 있지 않다. 본 논문에서는 항산화 효과 및 신경보호 효과가 있는 것으로 알려진 레스베라트롤을 고셔병 환자의 fibroblast 세포에 투여하여 세포 생존율 변화 여부 및 세포주기 조절에 관하여 분자 생물학적 기전을 알아보고자 하였다. 고셔병 세포의 p21의 mRNA 발현 수준과 단백질 발현 양상을 확인한 결과 mRNA 상의 정량적 차이는 관찰되지 않았으나 단백질 발현수준은 레스베라트롤의 농도가 높아짐에 따라 증가 되는 것을 확인하였다. 또한 세포사멸의 표지 인자 단백질로 알려진 PARP의 변화양상을 확인한 결과 레스베라트롤의 농도가 높아짐에 따라 감소하는 것을 확인 할 수 있었다. 이를 통해 폴리페놀계 천연물인 레스베라트롤이 고셔병에서 세포 손상을 치유하며, 궁극적으로 세포사멸을 억제하는 효과를 가져올 것으로 생각할 수 있으며, 본 질환에서 병증을 완화 시킬 수 있을 것으로 사료된다.

Keywords

References

  1. Ahmad, N., V. M. Adhami, F. Afaq, D. K. Feyes, and H. Mukhtar. 2001. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res. 7, 1466-1473.
  2. Almond, J. B., and G. M. Cohen. 2002. The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433-443. https://doi.org/10.1038/sj.leu.2402417
  3. Baur, J. A., and D. A. Sinclair. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506. https://doi.org/10.1038/nrd2060
  4. Berger, J., S. Lecourt, V. Vanneaux, C. Rapatel, S. Boisgard, C. Caillaud, N. Boiret-Dupre, C. Chomienne, J. P. Marolleau, J. Larghero, and M. G. Berger. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br. J. Haematol. 150, 93-101.
  5. Cal, C., H. Garban, A. Jazirehi, C. Yeh, Y. Mizutani, and B. Bonavida. 2003. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anticancer Agents 3, 77-93. https://doi.org/10.2174/1568011033353443
  6. Chen, Y., S. H. Tseng, H. S. Lai, and W. J. Chen. 2004. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136, 57-66. https://doi.org/10.1016/j.surg.2004.01.017
  7. Goker-Alpan, O., R. Schiffmann, J. K. Park, B. K. Stubblefield, N. Tayebi, and E. Sidransky. 2003. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J. Pediatr. 143, 273-276. https://doi.org/10.1067/S0022-3476(03)00302-0
  8. Lichtinghagen, R., P. B. Musholt, M. Lein, A. Romer, B. Rudolph, G. Kristiansen, S. Hauptmann, D. Schnorr, S. A. Loening, and K. Jung. 2002. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology 42, 398-406. https://doi.org/10.1016/S0302-2838(02)00324-X
  9. Pastores, G. M., M. J. Patel, and H. Firooznia. 2000. Bone and joint complications related to Gaucher disease. Curr. Rheumatol. Rep. 2, 175-180. https://doi.org/10.1007/s11926-000-0059-x
  10. Roversi, F. M., L. C. Galdieri, B. H. Grego, F. G. Souza, C. Micheletti, A. M. Martins, and V. D'Almeida. 2006. Blood oxidative stress markers in Gaucher disease patients. Clin. Chim. Acta. 364, 316-320. https://doi.org/10.1016/j.cca.2005.07.022
  11. Shen, J. S., X. L. Meng, D. F. Moore, J. M. Quirk, J. A. Shayman, R. Schiffmann, and C. R. Kaneski. 2008. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 95, 163-168. https://doi.org/10.1016/j.ymgme.2008.06.016
  12. Wei, H., S. J. Kim, Z. Zhang, P. C. Tsai, K. E. Wisniewski, and A. B. Mukherjee. 2008. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 17, 469-477. https://doi.org/10.1093/hmg/ddm324

Cited by

  1. Therapeutic Potential of Resveratrol in Type I Gaucher Disease vol.29, pp.6, 2015, https://doi.org/10.1002/ptr.5304
  2. Resveratrol Induces Apoptosis through PI3K/Akt and p53 Signal Pathway in MDA-MB-231 Breast Cancer Cells vol.44, pp.4, 2012, https://doi.org/10.9721/KJFST.2012.44.4.452